Xiu-Lan Zhao

Xiu-Lan Zhao

Auto-generated profile, based on publicly available information

Xiu-Lan Zhao

Department of Pathology, Tianjin Medical University, Tianjin, China

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2012 in Cancer Biology & Therapy
Verified
Journal Article
Closed access
PDF file
DZDanfang Zhang
Danfang Zhang
BSBaocun Sun
Baocun Sun
XZXiulan Zhao
Xiulan Zhao
YCYanfen Cui
Yanfen Cui
SXShaoyan Xu
Shaoyan Xu
JCJiadong Chi
Jiadong Chi
Triple-negative breast cancer, which is negative for the estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2, represents about 15-26% of all breast cancer cases. However, because of its genotype, a triple-negative disease accounts for a remarkable metastasis and mortality. Moreover, no targeted treatment is available because the molecular mechanism of triple-negative breast cancer initiation is still unclear. Secreted clusterin (sCLU) is associated with the refractory to anti-estrogen in breast cancer cells. We investigated the sCLU expression in 384 human breast cancer cases, including 61 triple-negative cases, as well as the relationship between sCLU and clinical pathological characteristics. Triple-negative patients (75.4%) were positive for sCLU based on immunohistochemical analysis, and sCLU expression in this subtype was proven related to a larger tumor size, an axillary node status, and a higher clinical stage. Furthermore, we used a spontaneous breast cancer mouse strain with a triple-negative genotype to detect the sCLU dynamic expression in breast cancer oncogenesis using western blot and real-time polymerase chain reaction. The sCLU mRNA and protein expression in the tumor and hyperplastic epithelium were upregulated and reached a peak compared with those of a normal mammary gland. These results suggest that sCLU is involved in the initiation of triple-negative breast cancer, which is beneficial for the clinical trial design of an anti-CLU treatment for triple-negative breast cancer.


1 November 2003
Verified
Journal Article
Closed access
XHXi-Shan Hao
Xi-Shan Hao
BSBao-Cun Sun
Bao-Cun Sun
SZShi-Wu Zhang
Shi-Wu Zhang
XZXiu-Lan Zhao
Xiu-Lan Zhao

1 December 2003
Verified
Journal Article
Closed access
BSBao-Cun Sun
Bao-Cun Sun
SZShi-Wu Zhang
Shi-Wu Zhang
XZXiu-Lan Zhao
Xiu-Lan Zhao
XHXi-Shan Hao
Xi-Shan Hao

1 September 2009
Verified
Journal Article
Closed access
YGYan Gao
Yan Gao
XZXiu-Lan Zhao
Xiu-Lan Zhao
QGQiang Gu
Qiang Gu
JWJun-Yan Wang
Jun-Yan Wang
SZShi-Wu Zhang
Shi-Wu Zhang
BSBao-Cun Sun
Bao-Cun Sun

1 March 2012 in Human Pathology
Verified
Journal Article
Closed access
YPYi Pan
Yi Pan
XZXiulan Zhao
Xiulan Zhao
JYJilong Yang
Jilong Yang
JDJingyu Deng
Jingyu Deng
ZZZhongli Zhan
Zhongli Zhan
BSBaocun Sun
Baocun Sun